ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced the following senior management appointments:
- James A. Nash, Senior Vice President, Technology Development and Operations
- Ryan E. Brown, Vice President, Chief Compliance Officer
- Fred W. Manak, Jr., Vice President, Access and Reimbursement
- Bob Mischler, Vice President, Strategy and Business Development
“We are pleased to have these strong and experienced leaders join the ACADIA team,” said Steve Davis, ACADIA’s Interim Chief Executive Officer. “We look forward to their contributions as we prepare for our New Drug Application submission and planned commercial launch of NUPLAZID™ (pimavanserin) for Parkinson’s disease psychosis in the United States, and as we seek to optimize the opportunities for pimavanserin in other disease states.”
James A. Nash, Senior Vice President, Technology Development and Operations
Mr. Nash joins ACADIA as Senior Vice President, Technology Development and Operations. In this new role, he is responsible for pharmaceutical development, manufacturing and GMP quality assurance. Mr. Nash brings over 30 years of executive level experience in these key technical functions. Prior to joining ACADIA, Mr. Nash served as Vice President, Technology Development and Operations at ViroPharma Inc. from 2008 to 2014, where he established supply chain, quality assurance and process development organizations in a rapidly growing specialty pharmaceutical company and supported the successful launch of Cinryze® for the treatment of hereditary angioedema. Previously, Mr. Nash served as Executive Vice President, Technical Operations at Watson Laboratories, Inc. where he led manufacturing, quality, and sourcing, managing seven manufacturing locations worldwide, and significantly enhancing the company’s operating efficiencies for delivering commercial products. He also has held executive positions in manufacturing at Chiron Corporation, Millennium Pharmaceuticals, Inc., and Searle Pharmaceuticals, Inc. Mr. Nash received his Bachelor of Arts degree in Zoology from the University of California, Berkeley and a Master of Business Administration from Northwestern University.
Ryan E. Brown, Vice President, Chief Compliance Officer
Mr. Brown joins ACADIA as Vice President, Chief Compliance Officer. In this new role, he is responsible for developing, implementing, and managing the Company’s corporate compliance program to support the planned commercialization of NUPLAZID and other future product opportunities. Prior to joining ACADIA, he served as Vice President, Chief Compliance Officer at Allergan, Inc. where he was responsible for the strategic vision and management of the global corporate compliance program and held other senior positions including General Counsel for subsidiary SkinMedica and Chief of Staff to the Office of the President. Mr. Brown received his Bachelor of Arts degree in Political Science from Loyola Marymount University and his Juris Doctor degree from Harvard Law School.
Fred W. Manak, Jr., Vice President, Access and Reimbursement
Mr. Manak joins ACADIA as Vice President, Access and Reimbursement. In this new role, he is responsible for establishing ACADIA’s access and reimbursement strategy to support the planned commercialization of NUPLAZID and other future product opportunities. In addition, Mr. Manak is responsible for managing the Company’s government affairs efforts. Mr. Manak brings over 25 years of industry experience, primarily in pharmaceutical access, reimbursement, pricing, and contracting. Previously, Mr. Manak served as Vice President, Market Access at InterMune, Inc. where he led the market access strategy for the launch of Esbriet® in idiopathic pulmonary fibrosis. Prior to joining InterMune, he served as Vice President, Reimbursement, Access and Value at Onyx Pharmaceuticals, Inc., and as Executive Director, Trade, Pricing and Contract Management at Amgen, Inc. Mr. Manak received his Bachelor of Science in Chemistry fromMuhlenberg College.
Bob Mischler, Vice President, Strategy and Business Development
Mr. Mischler joins ACADIA as Vice President, Strategy and Business Development. In this new role, he is responsible for strategic planning and business development initiatives. Prior to joining ACADIA, Mr. Mischler served as Vice President, Scientific Affairs and Business Development at Ardea Biosciences, a member of the AstraZeneca Group, where he led the development and implementation of its lifecycle management strategy for the global gout franchise. Previously, he served as Vice President, Commercial Planning and Analytics at Ardea Biosciences, where he was significantly involved in business development and led commercial activities. Earlier in his career, he worked in various roles focused on product and portfolio strategy at CovX Research LLC, Pfizer Inc. and Eli Lilly and Company. Mr. Mischler received his Bachelor of Science in Biologic Sciences from Indiana University and his Master of Business Administration from the UCLA Anderson School of Management. (Original Source)
Shares of Acadia closed yesterday at $47.7 . ACAD has a 1-year high of $51.99 and a 1-year low of $19.90. The stock’s 50-day moving average is $45.09 and its 200-day moving average is $38.67.
On the ratings front, Acadia has been the subject of a number of recent research reports. In a report issued on July 1, H.C. Wainwright analyst Andrew Fein maintained a Buy rating on ACAD, with a price target of $50, which represents a slight upside potential from current levels. Separately, on May 8, Needham’s Alan Carr maintained a Buy rating on the stock and has a price target of $38.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Andrew Fein and Alan Carr have a total average return of 26.2% and 42.7% respectively. Fein has a success rate of 61.6% and is ranked #110 out of 3724 analysts, while Carr has a success rate of 75.6% and is ranked #4.
The street is mostly Bullish on ACAD stock. Out of 6 analysts who cover the stock, 6 suggest a Buy rating . The 12-month average price target assigned to the stock is $43.80, which implies a downside of 8.2% from current levels.
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the business of development and commercialization of small molecule drugs for the treatment of central nervous system disorders.